Impaired Protein Tolerance Test as a Marker of Early Renal Dysfunction in Type 2 Diabetes Mellitus by Punitha, D P
“IMPAIRED PROTEIN TOLERANCE TEST” 
AS A MARKER OF EARLY RENAL 
DYSFUNCTION IN TYPE 2 DIABETES 
MELLITUS 
 
 
 
Dissertation Submitted for 
 
 
MD Degree (Branch I) General Medicine 
March 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Tamilnadu Dr.M.G.R.Medical University 
Chennai – 600 032. 
 
MADURAI MEDICAL COLLEGE, MADURAI. 
 
 
 
 
 
 
CERTIFICATE 
 
This is to certify that this dissertation titled “Impaired Protein 
tolerance test’’ as a marker of early Renal dysfunction in Type 2 
Diabetes Mellitus” submitted by DR.D.P.PUNITHA to the faculty of 
General Medicine, The Tamil Nadu Dr. M.G.R. Medical University, 
Chennai in partial fulfilment of the requirement for the award of MD 
degree branch I General Medicine, is a bonafide research work carried 
out by her under our direct supervision and guidance. 
 
 
 
DR. S.VADIVELMURUGAN, M.D., DR.A.AYYAPPAN, M.D., 
Professor of Medicine,      Professor and Head 
Chief, IV Medical Unit,               Department of Medicine, 
Department of Medicine,     Madurai Medical College, 
Madurai Medical College,    Madurai 
Madurai.  
 
 
 
 
 
 
DECLARATION 
 
 
I, Dr.D.P.Punitha, solemnly declare that the dissertation titled 
“Impaired Protein tolerance test’’ as a marker of early Renal 
dysfunction  in Type 2 Diabetes Mellitus” has been prepared by me. 
This is submitted to The Tamil Nadu Dr. M.G.R. Medical University, 
Chennai, in partial fulfilment of the regulations for the award of MD 
degree (branch I) General Medicine. 
 
 
Place: Madurai 
Date:        Dr.D.P.Punitha 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENT  
At the outset, I thank our Dean Dr. S.M.SHIVAKUMAR, M.S., 
for permitting me to use the facilities of Madurai Medical College and 
Government Rajaji Hospital to conduct this study.  
I wish to express my respect and sincere gratitude to my beloved 
teacher and Head of the Department of Medicine, PROF.A.AYYAPPAN, 
M.D., for his valuable guidance and encouragement throughout the study 
and also during my post graduate course. I owe my sincere thanks to him. 
I also owe my sincere thanks to my beloved unit chief and my 
guide PROF. S.VADIVELMURUGAN, M.D., for his guidance and 
support throughout the conduct of the study and also during my post 
graduate course.  
I express my special thanks to the Professor and Head, Department 
of Diabetology, PROF.A.J.ASIRVATHAM, M.D., D.Diab, for his 
valuable guidance.  
I sincerely thank the Professor and Head, Department of 
Nephrology, PROF.SHANMUGAPERUMAL, M.D., D.M, for his 
valuable support. 
I am greatly indebted to my beloved teachers, Dr. Daniel. K. 
Moses M.D., Dr.D.D.Venkatraman M.D., Dr.M.Muthiah, M.D., Dr. 
V.T.Premkumar M.D., Dr.Natarajan M.D., Dr.Sangumani,M.D. 
       I also wish to express my respect and sincere gratitude to my beloved 
Professor M.D., Dr.Nalini Ganesh M.D., Dr. P.Selvaraj M.D., and Dr. 
M.Kamaraj M.D .I owe them a lot and sincerely thank them. 
I am extremely thankful to my unit Assistant Professor 
Dr.Dharmaraj M.D., Dr.A.Senthamarai,M.D., My sincere thanks to 
my former Assistant Professors Dr.R.Balajinathan,M.D.,       
Dr.SheelaGanesh,M.D., Dr.Maniappan M.D., Dr.R.Sundaram,M.D.  
and Dr.Ramakrishnan, M.D., for their constant encouragement, timely 
help and critical suggestions throughout the study and also for making my 
stay in the unit both informative and pleasurable. 
I profusely thank the Biochemistry, Diabetology and Nephrology 
Departments for their cooperation and support.  
I extend my thanks to my family and friends have stood by me 
during my times of need. Their help and support have been invaluable to 
the study. 
Finally, I thank all the patients, who form the most integral part of 
the work, were always kind and cooperative. I pray for their speedy 
recovery and place this study as a tribute to them. 
 
 
 
 
CONTENTS 
S NO.  CONTENTS    PAGE NO 
1.    INTRODUCTION      1  
2.   REVIEW OF LITERATURE                          4 
3.    AIMS AND OBJECTIVES                           28 
4.   MATERIALS AND METHODS                  29 
5.   RESULTS AND ANALYSIS                       32 
6.   DISCUSSION                                               46 
7.    SUMMARY             50 
8.   CONCLUSION                                             51 
9.    APPENDIX 
BIBLIOGRAPHY 
PROFORMA 
MASTER CHART 
ETHICAL COMMITTEE APPROVAL FORM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations 
AGEs -advanced glycosylation end products 
AT- Angiotensin 
BG – Blood Glucose 
BMI – Body Mass Index 
BS-Blood Sugar 
CAD- Coronary Artery Disease 
CKD-Chronic Kidney Disease 
DM-  Diabetes Mellitus 
DN-Diabetic Nephropathy 
IDF-International Diabetes Federation  
ESRD-End-Stage Renal Disease 
e-GFR-Estimated Glomerular Filtration Rate 
GTT-Glucose Tolerance Test 
MDRD-Modification of Diet in Renal Disease 
PCR-Protein Creatinine Ratio 
PTT-Protein Tolerance Test 
SC-Serum Creatinine 
TGF-β Transforming growth factor β 
TScr -Tubular Secretion of creatinine  
VEGF -vascular endothelial growth factor  
 INTRODUCTION  
 
        India is frequently referred to as the diabetic capital of the world. Diabetes 
mellitus is widely prevalent in our country and its incidence is rising in 
alarming proportions. The worldwide prevalence1 of diabetes has risen 
dramatically over the past two decades, from an estimated 30 million cases in 
1985 to 177 million in 2000. Based on current trends, >360 million individuals 
worldwide will have diabetes by the year 2030. Although the prevalence of 
both type 1 and type 2 diabetes is increasing worldwide, the prevalence of type 
2 diabetes is rising much more rapidly because of increasing obesity and 
reduced activity levels as countries become more industrialized. Worldwide 
estimates project that in 2030 the greatest number of individuals with diabetes 
will be 45–64 years of age   .
According to the Diabetes Atlas published by the International Diabetes 
Federation (IDF), there are an estimated 40 million persons with diabetes in 
India in 2007, now it has risen to 60 million in 2009 and this number is 
predicted to rise to almost 120 million people in 2025 by which time every fifth 
diabetic subject in the world would be an Indian. Diabetes is a major cause of 
mortality, but several studies indicate that diabetes is likely under reported as a 
cause of death. A recent estimate suggested that diabetes was the fifth leading 
cause of death worldwide and was responsible for almost 3 million deaths 
annually (1.7–5.2% of deaths worldwide). 
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 Diabetes is the most common cause of kidney failure2, accounting for 
nearly 44 percent of new cases.  More than 100,000 people are diagnosed with 
kidney failure, a serious condition in which the kidneys fail to rid the body of 
wastes. Kidney failure is the final stage of chronic kidney disease (CKD). Even 
when diabetes is controlled, the disease can lead to CKD and kidney failure. 
Most people with diabetes do not develop CKD that is severe enough to 
progress to kidney failure. There are interplay of factors leading to kidney 
disease of diabetes—factors3 including heredity, diet, and other medical 
conditions, such as high blood pressure. It has been found that high blood 
pressure and high levels of blood glucose increase the risk that a person with 
diabetes will progress to kidney failure. So there is a need to identify 
subnormal kidney function4 at an earlier stage in order to initiate treatment in 
retarding the progression of kidney damage. Glucose tolerance test (GTT) has 
been used to assess the patient at risk of diabetes mellitus. The stress of glucose 
load in GTT unravels the patient with marginal pancreatic dysfunction. It has 
been suggested that analogous to GTT, a protein tolerance test (PTT) may help 
in identifying individuals with subnormal renal function before they manifest 
clinically. Increased serum creatinine level is often considered the first sign of 
a renal problem, but now, it may not be so. Microalbuminuria, another test to 
detect early renal dysfunction has now been used as a marker of endothelial 
dysfunction. By the time the serum creatinine levels increase, a good amount of 
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irreversible kidney damage is done .so, now this stresses the need for the 
tolerance test on the kidney in patients who have low glomerular filtration rate.  
 
An acute oral protein load causes a transient hyperfiltration that might 
reveal a loss of glomerular permselectivity properties .So, acute protein load 
test is of great utility in revealing a silent glomerular filtration disturbance.  
The stress of PTT will enable us to determine individuals with impaired 
functional reserve. The present study utilises this principle to identify those 
patients with diabetes who are at risk of developing renal failure. 
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REVIEW OF LITERATURE 
DIABETES MELLITUS 
Diabetes mellitus (DM) refers to a group of metabolic disorders which 
have a common denominator namely hyperglycemia. Factors contributing to 
hyperglycemia include reduced insulin secretion, decreased glucose utilization, 
and increased glucose production. The metabolic dysregulation associated with 
DM causes secondary pathophysiologic changes in multiple organ systems that 
impose a tremendous burden on the individual with diabetes and on the health 
care system.5  
 
Classification 
DM is classified on the basis of the pathogenic process that leads to 
hyperglycemia. The two broad categories of DM are designated type 1 and  
type 2.  
 - Type 1 diabetes is the result of complete or near-total insulin deficiency.  
- Type 2 DM is a heterogeneous group of disorders characterized by variable 
degrees of insulin resistance, impaired insulin secretion, and increased glucose 
production. Type 2 DM is preceded by a period of abnormal glucose 
homeostasis classified as impaired fasting glucose (IFG) or impaired glucose 
tolerance (IGT). 
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ETIOLOGIC CLASSIFICATION OF DIABETES MELLITUS 
I. Type 1 diabetes (β-cell destruction, usually leading to absolute insulin 
deficiency) 
  A. Immune-mediated 
  B. Idiopathic 
II. Type 2 diabetes (may range from predominantly insulin resistance with 
relative insulin deficiency to a predominantly insulin secretory defect with 
insulin resistance) 
III. Other specific types of diabetes 
  A. Genetic defects of beta cell function characterized by mutations in 
1. Hepatocyte nuclear transcription factor (HNF) 4 (MODY 1) 
2. Glucokinase (MODY 2)  
3. HNF-1 (MODY 3) 
    4. Insulin promoter factor-1 (IPF-1; MODY 4) 
5. HNF-1 (MODY 5) 
6. NeuroD1 (MODY 6) 
          7. Mitochondrial DNA 
          8. Subunits of ATP-sensitive potassium channel 
          9. Proinsulin or insulin conversion 
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B. Genetic defects in insulin action 
          1. Type A insulin resistance 
          2. Leprechaunism 
          3. Rabson-Mendenhall syndrome 
          4. Lipodystrophy syndromes 
  C. Diseases of the exocrine pancreas—pancreatitis, pancreatectomy, neoplasia, 
cystic fibrosis, hemochromatosis, fibrocalculous pancreatopathy, mutations in 
carboxyl ester lipase. 
  D. Endocrinopathies—acromegaly, Cushing's syndrome, glucagonoma, 
pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma 
  E. Drug- or chemical-induced—Vacor, pentamidine, nicotinic acid, 
glucocorticoids, thyroid hormone, diazoxide, beta-adrenergic agonists, 
thiazides, phenytoin, protease inhibitors, clozapine 
  F. Infections—congenital rubella, cytomegalovirus, coxsackie 
  G. Uncommon forms of immune-mediated diabetes—"stiff-person" syndrome, 
anti-insulin receptor antibodies 
  H. Other genetic syndromes sometimes associated with diabetes—Down's 
syndrome, Klinefelter's syndrome, Turner's syndrome, Wolfram's syndrome, 
Friedreich's ataxia, Huntington's chorea, Laurence-Moon-Biedl syndrome, 
myotonic dystrophy, porphyria, Prader-Willi syndrome 
IV. Gestational diabetes mellitus (GDM) 
Glucose intolerance may develop during pregnancy. Insulin resistance is 
related to the metabolic changes of late pregnancy and the increased insulin 
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requirements may lead to IGT. GDM occurs in ~4% of pregnancies in the 
United States; most women revert to normal glucose tolerance post-partum but 
have a substantial risk (30–60%) of developing DM later in life. 5 
 
Diagnosis of diabetes mellitus 
The National Diabetes Data Group and World Health Organization (WHO) 
have issued certain diagnostic criteria: 
• Symptoms of diabetes plus random blood glucose concentration 11.1 
mmol/L (200 mg/dL)a (or)  
• Fasting plasma glucose 7.0 mmol/L (126 mg/dL)b (or)  
• Two-hour plasma glucose 11.1 mmol/L (200 mg/dL) during an oral 
glucose tolerance testc 
aRandom is defined as without regard to time since the last meal. 
bFasting is defined as no caloric intake for at least 8 h. 
cThe test should be performed using a glucose load containing the equivalent of 
75gms anhydrous glucose dissolved in water; not recommended for routine 
clinical use. 
Glucose tolerance is classified into three categories based on the FPG:  
 (1) FPG < 5.6mmol/L (100 mg/dL) is considered normal 
 (2) FPG = 5.6–6.9 mmol/L (100–125 mg/dL) is defined as IFG 
 (3) FPG ≥ 7.0 mmol/L (126 mg/dL) warrants the diagnosis of DM. 
Based on the OGTT, IGT is defined as plasma glucose levels between 7.8 and 
11.1 mmol/L (140 and 199 mg/dL) and diabetes is defined as a glucose > 11.1 
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mmol/L (200 mg/dL) 2 h after a 75-g oral glucose load. Some individuals have 
both IFG and IGT. Individuals with IFG and/or IGT, recently designated ‘pre-
diabetes’ by the American Diabetes Association (ADA), are at substantial risk 
for developing type 2 DM (25–40% risk over the next 5 years) and have an 
increased risk of cardiovascular disease. 6
Risk Factors for Type 2 Diabetes Mellitus 
1. Family history of diabetes (i.e., parent or sibling with type 2 diabetes)  
2. Obesity (BMI >25 kg/m2)  
3. Habitual physical inactivity 
4. Race/ethnicity (e.g., African American, Latino, Native American, Asian 
American, Pacific Islander)  
5. Previously identified IFG or IGT  
6. History of GDM or delivery of baby >4 kg (>9 lb)  
7. Hypertension (blood pressure >140/90 mmHg)  
8. HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or a triglyceride level 
>250 mg/dL (2.82 mmol/L)  
9. Polycystic ovary syndrome or acanthosis nigricans  
10. History of vascular disease 
 
Pathophysiology 
Type 2 DM is characterized by impaired insulin secretion, insulin 
resistance, excessive hepatic glucose production, and abnormal fat metabolism. 
Obesity, particularly visceral or central (as evidenced by the hip-waist ratio), is 
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very common in type 2 DM. In the early stages of the disorder, glucose 
tolerance remains near-normal, despite insulin resistance, because the 
pancreatic beta cells compensate by increasing insulin output. As insulin 
resistance and compensatory hyperinsulinemia progress, the pancreatic islets in 
certain individuals are unable to sustain the hyperinsulinemic state. IGT, 
characterized by elevations in postprandial glucose, then develops. A further 
decline in insulin secretion and an increase in hepatic glucose production lead 
to overt diabetes with fasting hyperglycemia. Ultimately, beta cell failure may 
ensue.7 
                                 
                                        DIABETIC NEPHROPATHY 
   The natural history of Diabetic Nephropathy in patients with type 2 DM is 
less well understood than in patients with type 1 DM. This partly reflects the 
fact that type 2 DM is largely a disease of an older population with associated 
obesity ,hypertension ,dyslipidemia and high rates of cardiovascular disease 
that restrict the manifestation of renal disease. In addition approximately 7% of 
the patients with type 2 DM already have microalbuminuria at the time of 
diagnosis.With in 5 years of diagnosis 18% have microalbuminuria especially 
those with poor metabolic control and high blood pressure levels8. 
    It is commoner to see more patients of type 2 DM with nephropathy than 
those with type 1 DM (9:1) even though the incidence of nephropathy is high in 
type 1 DM(30%) when compared to type 2 DM(20%)9 
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Definition 
   Nephropathy is one of the commonest complications of type 2 diabetes 
mellitus. Diabetic nephropathy10 (DN) is typically defined by 
macroalbuminuria—that is, a urinary albumin excretion of more than 300 mg 
in a 24-hour collection and abnormal renal function as represented by an 
abnormality in serum creatinine, calculated creatinine clearance, or glomerular 
filtration rate (GFR). Clinically, diabetic nephropathy is characterized by a 
progressive increase in proteinuria and decline in GFR, hypertension, and a 
high risk of cardiovascular morbidity and mortality11. 
Prevalence and risk factors12
Diabetes has become the primary cause of end-stage renal disease (ESRD) in 
the United States, and the incidence of type 2 diabetes mellitus continues to 
grow in the United States and worldwide. Approximately 44% of new patients 
entering dialysis in the United States are diabetics. Approximately 20% to 30% 
of all diabetics will develop evidence of nephropathy, although a higher 
percentage of type 1 patients progress to ESRD13. 
Risk factors for diabetic nephropathy14 include: 
-African American, Hispanic, or American Indian origin 
-Family history of kidney disease or high blood pressure 
-Poor control of blood pressure 
-Poor control of blood sugars 
-Type 1 diabetes before age 20 
-Smoking 
 10
Diabetic nephropathy generally coexists along with other diabetes 
complications including hypertension, retinopathy, and atherosclerosis. 
Pathophysiology and natural history 
The common progression from microalbuminuria to overt nephropathy 
has led many to consider microalbuminuria to define early or incipient 
nephropathy.15 Renal disease is suspected to be secondary to diabetes in the 
clinical setting of long-standing diabetes. This is supported by the history of 
diabetic retinopathy, particularly in type 1 diabetics, in whom there is a strong 
correlation. The natural history of diabetic nephropathy is a process that 
progresses gradually over years. 
Early diabetes is heralded by glomerular hyperfiltration and an increase 
in GFR. This is believed to be related to increased cell growth and expansion in 
the kidneys, possibly mediated by hyperglycemia itself.  Microalbuminuria 
typically occurs after 5 years in type 1 diabetes.16 Overt nephropathy, with 
urinary protein excretion higher than 300 mg/day, often develops after 10 to 15 
years. ESRD develops in 50% of type 1 diabetics, with overt nephropathy 
within 10 years. 
Type 2 diabetes has a more variable course. Patients often present at 
diagnosis with microalbuminuria because of delays in diagnosis and other 
factors affecting protein excretion. Fewer patients with microalbuminuria 
progress to advanced renal disease. Without intervention, approximately 30% 
progress to overt nephropathy and, after 20 years of nephropathy, 
approximately 20% develop ESRD. Because of the high prevalence of type 2 
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compared with type 1 diabetes; however, most diabetics on dialysis are type 2 
diabetics. 
Long-standing hyperglycemia is known to be a significant risk factor for 
the development of diabetic nephropathy.17 Hyperglycemia may directly result 
in mesangial expansion and injury by an increase in the mesangial cell glucose 
concentration. The glomerular mesangium expands initially by cell 
proliferation and then by cell hypertrophy. Increased mesangial stretch and 
pressure can stimulate this expansion, as can high glucose levels.18 
Transforming growth factor β (TGF-β) is particularly important in the 
mediation of expansion and later fibrosis via the stimulation of collagen and 
fibronectin. Glucose can also bind reversibly and eventually irreversibly to 
proteins in the kidneys and circulation to form so-called advanced 
glycosylation end products (AGEs) 19. AGEs can form complex cross-links 
over years of hyperglycemia and can contribute to renal damage by stimulation 
of growth and fibrotic factors via receptors for AGEs. In addition, mediators of 
proliferation and expansion, including platelet-derived growth factor, TGF-β, 
and vascular endothelial growth factor (VEGF) that are elevated in diabetic 
nephropathy can contribute to further renal and microvascular complications. 
Proteinuria, a marker and potential contributor to renal injury, 
accompanies diabetic nephropathy. Increased glomerular permeability will 
allow plasma proteins to escape into the urine. Some of these proteins will be 
taken up by the proximal tubular cells, which can initiate an inflammatory 
response that contributes to interstitial scarring eventually leading to fibrosis. 
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Tubulointerstitial fibrosis is seen in advanced stages of diabetic nephropathy 
and is a better predictor of renal failure than glomerular sclerosis. 
Hyperglycemia, angiotensin II, TGF-β, and likely proteinuria itself all play 
roles in stimulating this fibrosis.20 There is an epithelial-mesenchymal 
transition that takes place in the tubules, with proximal tubular cell conversion 
to fibroblast-like cells. These cells can then migrate into the interstitium and 
produce collagen and fibronectin21. In diabetic nephropathy, the activation of 
the local renin-angiotensin system occurs in the proximal tubular epithelial 
cells, mesangial cells, and podocytes. Angiotensin II (ATII) itself contributes to 
the progression of diabetic nephropathy. ATII is stimulated in diabetes despite 
the high-volume state typically seen with the disease, and the intrarenal level of 
ATII is typically high, even in the face of lower systemic concentrations. ATII 
preferentially constricts the efferent arteriole in the glomerulus, leading to 
higher glomerular capillary pressures. In addition to its hemodynamic effects, 
ATII also stimulates renal growth and fibrosis through ATII type 1 receptors, 
which secondarily upregulate TGF-β and other growth factors. 
    Control of hypertension has clearly shown to be an important and powerful 
intervention in decreasing the progression of diabetic nephropathy.22 In 
diabetics who have disordered autoregulation at the level of the kidney, 
systemic hypertension can contribute to endothelial injury.23 Human studies of 
type 2 diabetics have shown that blood pressure lowering, regardless of the 
agent used, retards the onset and progression of diabetic nephropathy. In 
animal studies, the degree and severity of the diabetic nephropathy were 
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strongly linked to systemic blood pressure. The fact that most types 1 and 2 
diabetics do not develop diabetic nephropathy (DN) suggests that other factors 
may be involved. Genetic factors clearly play a role in the predisposition to 
diabetic nephropathy in family members who have DN, and linkage to specific 
areas on the human genome is evolving.24 The theory of a reduction in nephron 
number at birth indicates that individuals born with a reduced number of 
glomeruli may be predisposed to subsequent renal injury and progressive 
nephropathy. This has been shown in animal studies in which the mother was 
exposed to hyperglycemia at the time of pregnancy. If this linkage is true in 
humans, that would have important implications concerning the role of 
maternal factors in the eventual development of kidney disease. 
The Course of Kidney Disease in Diabetes 
Diabetic kidney disease takes many years to develop. In some people, the 
filtering function of the kidneys is actually higher than normal in the first few 
years of their diabetes. Over several years, people who are developing kidney 
disease will have small amounts of the blood protein albumin begin to leak into 
their urine. This first stage of CKD is called microalbuminuria. The kidney’s 
filtration function usually remains normal during this period. As the disease 
progresses, more albumin leaks into the urine.25 This stage may be called 
macroalbuminuria or proteinuria.  
As the amount of albumin in the urine increases, the kidneys’ filtering 
function usually begins to drop. The body retains various wastes as filtration 
falls. As kidney damage develops, blood pressure often rises as well. Overall, 
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kidney damage rarely occurs in the first 10 years of diabetes, and usually 15 to 
25 years will pass before kidney failure occurs. For people who live with 
diabetes for more than 25 years without any signs of kidney failure, the risk of 
ever developing it decreases. 
Diagnosis of CKD 
People with diabetes should be screened regularly for kidney disease.26 
Some of the abnormalities detected in renal dysfunction are as follows. 
 
 
The two key markers for kidney disease are eGFR and urine 
albumin.eGFR- eGFR stands for estimated glomerular filtration rate27. The 
calculation of eGFR is based on the amount of creatinine, a waste product, 
found in a blood sample. As the level of creatinine goes up, the eGFR goes 
down. Glomerular filtration rate (GFR) measures the amount of glomerular 
filtrate (a substance similar to the plasma part of blood but without the proteins) 
formed in the kidneys per minute. The results help indicate the kidney’s ability 
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to filter and remove waste products from the body. The following table shows 
the creatinine values corresponding to GFR.28
GFR is used to screen for early signs of kidney damage. In people already  
diagnosed with kidney disease (nephropathy), GFR is used to monitor the 
patient for signs of deterioration in kidney function. In general, values are 
interpreted based on the following table29: 
Stage of disease 
 
Description of condition 
GFR 
(mL/min/ 
1.73 mÂ²) 
At an increased 
risk 
Risk factors for kidney disease (e.g., diabetes, high blood 
pressure, family history of kidney disease, older age, 
ethnic group) 
More than 90 
1 Kidney damage (proteinuria) and normal GFR More than 90 
2 Kidney damage and slight decrease in GFR 60-89 
3 Moderate decrease in GFR 30-59 
4 Severe decrease in GFR 15-29 
5 Kidney failure Less than 15 
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The benefits of GFR include: 
-Measuring the filtering capacity of the kidneys. 
-Outlining the progression of kidney disease. 
-Predicting the time to onset of kidney failure. 
-Predicting the risk of complications of chronic kidney disease. 
-Providing physicians with information that may be needed for determining 
medication dosage. 
Types and differences of GFR 
The glomerular filtration rate (GFR) of the kidneys cannot be directly 
measured. However, various methods have been developed to provide indirect 
measurements and estimates.30
One such method is an inulin clearance test31. Inulin, a complex fructose 
sugar (a sugar found in fruit), is considered an ideal filtration marker for the 
measurement of GFR in humans. Inulin is injected into the patient and the 
amount of inulin filtered at the glomeruli (blood vessels in the kidney) 
normally equals the amount of excreted inulin. However, this method is not 
often used because it is costly, inconvenient and better suited for research 
studies. It is also difficult to perform on infants. 
The use of radioactive markers (radioactive marker clearance test) also 
provides an accurate measurement of GFR.32 However, they are not readily 
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available in many centers. The most commonly used measurements of GFR are 
serum creatinine tests and 24-hour creatinine clearance tests. 
Creatinine is a waste product that comes from two sources: meat 
products in the diet and muscle use. Almost all creatinine eventually ends up in 
a person’s urine. Creatinine measurements from blood and urine samples are 
used to calculate GFR because the chemical is normally present in the bodyand 
very little of it is reabsorbed. A serum creatinine test measures the level of 
creatinine in the blood.33
A creatinine clearance test compares the levels of creatinine in the urine 
and the blood, along with urine volume. A 24-hour urine sample is usually 
collected and a blood sample is taken from a vein, and the estimated GFR is 
calculated. 
There are certain drawbacks to using a creatinine clearance test to 
calculate GFR.34 These include: 
- Collecting a 24-hour urine sample may be inconvenient for the patient.  
- The level of creatinine excreted in urine varies. The levels differ from 
day to day, and thus even a 24-hour sample can yield inaccurate GFR 
estimations.  
- Errors are common during the collection of a urine sample, and these 
errors can influence test results. 
- Creatinine is secreted by the kidneys. In addition to being filtered by the 
kidneys, a small amount of creatinine is also secreted by the kidneys. As 
a result, the amount of creatinine excreted in the urine is the 
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combination of both the filtered and secreted creatinine and is not 
exactly equivalent to the GFR. This usually results in overestimating the 
GFR of the kidneys. 
Another method of estimating a patient’s GFR is by using a serum creatinine 
based prediction equation. These equations are more accurate in estimating 
GFR than serum creatinine measurements alone. Several equations have been 
developed. The equations are useful because they take into consideration that 
creatinine production varies according to age, gender, race or ethnicity, and 
muscle mass. All or some of these factors are then used along with the serum 
creatinine concentration to estimate a patient’s GFR. 
 
The Cockcroft-Gault and Jelliffe were originally developed for 
estimating creatinine clearance. However, they have been widely tested as 
predictors of GFR in adults. 
A newly developed equation, the MDRD Study equation, also provides 
an estimate of GFR in adults. The abbreviated version of the equation is based 
 19
on serum creatinine concentration, age, gender and race and is standardized for 
body surface area. The National Institute of Diabetes and Digestive and Kidney 
Diseases, the National Kidney Foundation and the American Society of 
Nephrology recommend estimating GFR from serum creatinine concentration 
using the MDRD Study equation.35
Equations to estimate GFR in children have also been developed.36 
Although imprecise, these equations are considered practical and convenient. 
They both estimate GFR based on a constant multiplied by the patient’s height 
(height is proportional to muscle mass) divided by the serum creatinine. The 
MDRD Study equation has not been widely tested in children and its’ 
reliability is unknown. 
There are some drawbacks to using prediction equations. One is that the 
equations are much less accurate at measuring a higher range of GFR, such as 
occurs in a healthy person or in the early stages of chronic kidney disease. As a 
result, other indications of early kidney disease, such as proteinuria 
(abnormally high levels of protein in the urine) are needed to detect early 
deterioration in kidney function. In newly diagnosed type 2 diabetic patients, 
particularly those with a GFR >/=90 ml/min per 1.73 m2, both CG and MDRD 
equations significantly underestimate eGFR. This highlights a limitation in the 
use of eGFR in the majority of diabetic subjects outside the setting of chronic 
kidney disease. 
There are also some situations in which the GFR estimate provided by a 
creatinine clearance test is more desirable than that based on a prediction 
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equation. This is because certain individual variations (e.g., diet and muscle 
mass) are not taken into consideration in prediction equations. These situations 
include: 
-Extremes of age 
-Extremes of body size 
-Disease of the skeletal muscles 
-Paraplegia or quadriplegia 
-Vegetarian diet 
-Use of creatine (dietary) supplements 
-Rapid changes in kidney function 
-Amputation 
-Malnutrition 
-Muscle wasting 
-Pregnancy 
Cystatin C test is another method of detecting and monitoring kidney 
malfunction. 37 Cystatin C is found in most cells, is filtered out of the blood by 
the glomeruli and forms a fluid filtrate. The cystatin C left in the filtrate is then 
reabsorbed by the body and not returned to the blood. When the kidneys 
malfunction, the blood levels of cystatin C increase, and the test can reflect the 
reduction in the formation of fluid filtrate. The increased levels of cystatin C 
may be detected before there is a decrease in the GFR. In addition, gender, 
muscle mass and race or ethnicity does not influence the test. The cystatin C 
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test may become a diagnostic standard in detecting kidney malfunction in the 
future. 
Once calculated, people's GFR can be used to measure their level of 
kidney function and/or determine their stage of kidney disease. 
 In general, an estimated GFR greater than or equal to 90 milliliters per minute 
per 1.73 square meters (mL/min/1.73 mÂ²) is normal. The 1.73 mÂ² value 
represents the average adult body surface area in square meters. 
An estimated GFR less than 90 mL/min/1.73 mÂ² is abnormal. 
However, normal value ranges may vary among laboratories. In addition 
to aging and kidney disease, there are several other factors that may affect GFR.  
Factors that can decrease GFR include: 
-Vascular diseases 
-Congestive heart failure
-Sodium and water depletion (dehydration) 
-Hemorrhage 
-Vigorous exercise 
-Shock 
Factors that can increase GFR include: 
-Dietary protein intake 
-Ketoacidosis 
-Hyperglycemia (high blood sugar) 
-Pregnancy 
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PROTEIN TOLERANCE TEST38
 In this test, a patient is exposed to high level of protein and 
his/her GFR is calculated in a span of two-three days, the GFR should increase 
by 20% without protein leaking into the urine. Glomerular Filtration Rate (GFR) 
is the most widely used indicator of kidney function in patients with renal 
disease. The severity and prognosis of the renal disease is often predicted on 
basis of this parameter alone. The recent K-DOQI39 guidelines also recommend 
the stratification of renal disease according to the GFR and other risk factors. 
Generally, it is a well accepted notion, that GFR is remarkably stable from day-
to-day over a period of years. However, in their pioneering report, Bosch et al  
described their findings in a group of studies performed to examine the 
influence of protein intake on GFR. 
A direct relationship was also found between the protein intake and 
GFR, i.e., with an increase in protein intake there was an increase in GFR in 
both short term and long term studies. The possibility of a variation in GFR and 
the capacity of kidney to augment its level of function suggest a renal 
functional reserve40. The renal functional reserve represents the capacity of the 
kidney to increase its level of operation under certain demands. This reserve 
may be considered analogous to the cardiac functional reserve. When increased 
physiological demands are placed on the heart, it responds with an increase in 
cardiac output. Similarly, when the kidneys are subjected to greater 
physiological demands, they also respond with an increase in GFR. 
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Conceptionally, the renal capacity to increase GFR from the baseline to a 
maximal one can alter the results of GFR studies. 
In renal diseases, this functional reserve increases GFR of the residual 
nephrons, replacing the lost function and maintaining the whole organ GFR.41 
Only after the residual nephrons can no longer compensate for the functional 
loss, will the changes in resting GFR and rise in serum creatinine occur. On the 
other hand, the patient with a renal disease on a low protein diet may have a 
reduction in GFR unrelated to the progression of renal disease. Resting GFR 
therefore is not only an insensitive index for early detection of renal disease but 
is also inappropriate for renal disease follow up. Glucose tolerance test (GTT) 
has been used to assess the patient at risk of diabetes mellitus. The stress of 
glucose load in GTT unravels the patient with marginal pancreatic dysfunction. 
It has been suggested that analogous to GTT, a protein tolerance test (PTT) 
may help in identifying individuals with subnormal renal function before they 
manifest clinically. The stress of PTT will enable us to determine individuals 
with impaired functional reserve.42 Thus PTT is a better test than resting GFR 
or serum creatinine 
Mechanisms of renal haemodynamic response to protein feeding43. 
An acute oral protein load causes a transient hyperfiltration that might reveal a 
loss of glomerular permeable selectivity properties. A protein meal, on 
digestion, which acutely raises the plasma amino acid concentration; this 
increase can also be mimicked by an intravenous amino acid infusion. These 
amino acids are filtered at the glomerulus and act directly on the kidney to 
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stimulate proximal tubular absorption in a healthy metabolic state. Amino acid 
may also change sensitivity of the macula densa sensing mechanisms by 
altering cell permeability. Sensing a reduced tubular sodium chloride 
concentration, the macula densa cells release EDRF and prostaglandins locally, 
which cause afferent arteriolar vasodilatation. This afferent vasodilatation 
results in increased blood flow and GFR. On the other hand, the patient with a 
renal disease on a low protein diet may have a reduction in GFR unrelated to 
the progression of renal disease. Resting GFR therefore is not only an 
insensitive index for early detection of renal disease but is also inappropriate 
for renal disease follow up. 
Utility of the protein tolerance test in clinical Nephrology 
The protein tolerance test can be utilised in: 
a. Assessing the baseline and progression of renal disease in certain high risk 
groups – especially in disorders known to have a subsequent decline in renal 
function – like diabetics, hypertensives, polycystic kidney disease patients, and 
patients with a solitary kidney. These patients can be accurately prognosticated 
and planned for more aggressive intervention if required, by testing with stress 
GFR as compared to resting GFR. 
b. Assessment of borderline donors. Due to shortage of live related donors, 
elderly and hypertensive individuals are now being taken up as potential renal 
donors. Stress GFR in atleast these high risk donors will be desirable to reject 
those who are likely to have renal compromise subsequently, though they 
might be having a normal resting GFR. 
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Procedure for conducting PTT44
The protein tolerance test has two components: 
1. Stress GFR 
2. Tubular stress test 
Stress GFR 
Patients should be fasting and should receive oral hydration with 20 ml/kg of 
water. Once hydration is complete, urine volume is replaced by an equal 
quantity of water. Endogenous creatinine clearance is used for assessing the 
test and baseline GFR. Baseline GFR– Two blood samples are collected for  
serum creatinine measurement at the start and 30 minutes apart for calculation 
of creatinine clearance by Cockroft and Gault equation (CG formula) and the 
mean is taken as baseline creatinine clearance. 
                                         Tubular stress test 
Purpose: To assess the functional reserve of the kidney by performing tubular 
function.  
Increase in tubular secretion of creatinine (TScr) after a test meat meal. They 
demonstrated that in normal individual TScr was three times the baseline, while 
patients with moderate renal failure were unable to raise their TScr. However, 
it requires standardisation and further studies to prove its utility. 
Interpretation 
Any individual with normal protein tolerance test will show an increase 
in GFR from baseline in absence of urinary protein. In contrast, those with 
abnormal test will have proteinuria and no increase in GFR. The maximal 
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filtration capacity attained after the protein load in various western studies is 
reported to be around 140 -160 ml/min/1.73 m2 with a percentage increase in 
GFR of 20 - 40% from basal state2, 3, 5. Increase in GFR without any 
proteinuria suggests normal response, while increase in GFR with proteinuria 
would suggest renal injury and no increase in GFR would suggest incipient 
renal failure. Hence, protein tolerance test can be used to ascertain an 
individual’s renal reserve, with incipient renal failure and Normal GFR and 
serum creatinine. Thus, appropriate measures can be initiated at the earliest in 
such cases. Not much literature is available at the moment in relation to this 
test. Only two studies have evaluated the protein tolerance test, one was way 
back in 1950 and one was in 2005 in india. Both the studies proved that protein 
tolerance test was a useful tool in identifying at risk patients. 
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AIMS AND OBJECTIVES 
 
The aims of the study were- 
1. To identify individuals with impaired protein tolerance test as a 
marker of early renal dysfunction in type 2 diabetes mellitus. 
         2. To compare individuals with impaired protein tolerance with normal 
population. 
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MATERIALS AND METHODS 
The study was conducted on patients attending the out patient 
department of Government Rajaji Hospital, Madurai. Approval from the 
hospital ethical committee was obtained.  
STUDY DESIGN 
The study was a case control study conducted for a period of one year 
between October 2008- September 2009.  
Inclusion criteria 
• Patients with type 2 diabetes mellitus were included in the study.  
• Fifty healthy, age and sex matched controls without diabetes or its 
complications were also included in the study for comparison. 
Exclusion criteria 
• Patients with type 2 diabetes mellitus with proteinuria 
• Systemic hypertension 
• Renal Failure 
Diagnosis of Type 2 diabetes mellitus was made by clinical details and 
routine blood investigations including fasting and postprandial blood sugar 
values. The WHO criteria were employed for the diagnosis of diabetes 
mellitus.2  
The presence of absence of renal dysfunction was made on the basis of the 
following: 
1. Clinical details 
2. Routine Blood investigations 
 29
3. Measurment of baseline creatinine clearance and. creatinine clearance 
after a protein meal( 100 gm of protein as cottage cheese ) 
4. Spot urinary protein estimation at baseline and after a protein meal. 
 METHODS 
 After the diagnosis of Type 2 diabetes mellitus,  
All the selected patients were subjected to a high protein meal. To detect 
renal dysfunction in type 2 diabetes mellitus, blood samples were collected 
after 8 hours of fasting for fasting blood sugar and after two hours of 
postprandial state. Blood samples were collected at 0, 30, 60 and 120 minutes  
for serum creatinine after giving high protein meal. Serum was separated and 
stored in the refrigerator. Serum creatinine was measured from this serum.  
e GFR was calculated by using Cockcroft-Gault equation 
Estimated creatinine clearance (mL/min) 
= (140-age x body weight in kg)/72 x Plasma creatinine (mg/dL) 
Urine samples were collected at 0, and 120 minutes for Urine PCR . 
The information collected regarding all the selected cases were recorded 
in a Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2008). Using this software, 
range, frequencies, percentages, means, standard deviations, chi square and ‘p’ 
values were calculated. Kruskul Wallis chi-square test was used to test the 
significance of difference between quantitative variables. A 'p' value less than 
0.05 is taken to denote significant relationship. 
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RESULTS AND STATISTICAL ANALYSIS 
 
EPIDEMIOLOGY 
Majority of the patients were from in and around Madurai city. The total 
number of patients included in the study was 52. Fifty controls were also 
included in the study for comparative analysis.  
Among the total of 52 Type 2 diabetes mellitus patients [Female (F)-24; 
Male (M)-28]  , 32 diabetic patients [Female (F)-16; Male (M)-16] had no 
evidence of Renal Dysfunction (Group-I), whereas 9 diabetic patients (F-4; 
M-5) had evidence of Renal injury(Group-II) and 11 diabetic patients (F-4; 
M-7) had evidence of incipient Renal Failure (Group-III) 
Out of the 50 controls, 24 were female and 26 were male, 2 diabetic 
patients (F-1; M-1) had evidence of renal injury (Group-II)  
The age of the controls ranged from 32 to 67 years with a mean age of 
52.1 years. The age of the patients in the study group ranged from 32-67 years 
with a mean of 54.11 years. In the study group, 9 patients were in the age group 
of upto 40 years (18%) , 15 patients in 41-50 age group  (30%), 22 patients in 
51-60 age group (44%),4 patients (8%) were in the age group of >60years. 
The age groups of the cases and controls were comparable and there 
was no statistical difference (p=0.3594). 
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 The age distribution of the patients are shown in tables 1  
                                           TABLE  1: Age distribution 
cases controls Age group 
No. % No. % 
Upto 40 years 2 3.8 9 18 
41-50      13   25 15 30 
51-60 31 59.6 22 44 
Above 60 years 6 11.5 4 8 
Total 52 100 44 100 
 
Mean 
S.D. 
 
54.11 
7.27 
 
52.1 
9.0 
 
 
The gender of the patients and controls were comparable. The sex 
distribution of the patients are shown in tables 2 . 
                          TABLE  2: Sex distribution 
         Cases Controls     Sex 
 No. % No. % 
Males 28 53.8 26 52 
Females 24 46.2 24 48 
Total 52 100 50 100 
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      It was observed that the number of female patients was equal in both 
control and study groups , but a slightly higher number of Male patients  
in control group (1:1.08).  
 
Patients and controls were classified as overweight, normal weight and 
underweight according to the body mass index. Out of 50 controls, 13 were in 
the underweight patients (26%), 25 were in the normal weight patients (50%) 
and12 were (24 %) in the overweight patients. In study group, 15 out of 52 
(28.8%) were in the underweight patients, 25 out of 52 (48.1%) were in the 
normal weight patients and 12 out of 52 (23’1%) were in the ov erweight 
patients.  
     The mean height, weight and BMI were comparable in both the 
groups. The results are shown in table 3. 
 
TABLE  3: BMI 
Cases Controls  
BMI No. % No. % 
Underweight< (18.5) 15 28.8 13 26 
Normal(18.5-24.9) 25 48.1 25 50 
Overweight (>25) 12 23.1 12 24 
‘p’ 0.9016 Not significant 
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The BMI of the above groups was comparable and there was no 
statistical difference (p=0.9016). 
 
        Urine PCR was analyzed in the two groups. The results are summarised  
in table 4.  
 
TABLE  4: Urine PCR 
Cases Controls Urine         PCR 
No. % No. % 
O min 
Normal 
Abnormal 
 
52 
- 
 
100 
- 
 
50 
- 
 
100 
- 
‘p’ - 
120 min 
Normal 
Abnormal 
 
32 
20 
 
61.5 
38.5 
 
48 
2 
 
96 
4 
‘p’ 0.0001 Significant 
 
. Urine PCR was more in the test group then the control group and both 
the values (0 and 120 min) were statistically significant (p=0.0001). 
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      Fasting (0 hr) and postprandial (2 hour) blood sugar values were analyzed 
in the two groups. The mean FPG in control group was 90.3mg/dl compared to 
154.5 mg/dl in study group. On the other hand mean 2 hour PPG values in 
control group were 129mg/dl as opposed to 254.8mg/dl in study group.  
Serum creatinine-1 (0, 30 min & mean) and post protein load Serum 
creatinine-2 levels (60, 120 min & mean) were analysed. The mean Serum 
creatinine-1 values were 0.86 mg/dl in control group, 0.91mg/dl in study group. 
The difference between the two groups was statistically not significant 
(p=0.0544). 
 The mean post protein load Serum creatinine-2 values were 0.72mg/dl 
in control group, 0.81mg/dl in study group. The difference between the two 
groups was statistically significant (p=0.0025). 
   The e GFR-1 mean value was 77.46 in the control group compared to 
72.28 in the study group .The difference between the two groups was not 
statistically significant (p=0.1016). 
  The e GFR-2 values remained persistently decreased with a mean of 
92.42 in the control group compared to 82.33 in the study group .The 
difference between the two groups was statistically significant (p=0.0008). 
The results are summarised in table 5. 
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 TABLE  5: Quantitative parameters 
 
 
Cases 
 
Controls 
 
Parameter 
Mean SD Mean SD 
 
‘p’ 
Weight(kgs) 
Height(cm) 
BMI 
Blood sugar(0 min) 
Blood sugar(120min) 
Duration 
Sr.creatinine(0min) 
Sr.creatinine(30min) 
Sr.creatinine1(mean) 
Sr.creatinine(60min) 
Sr.creatinine(120min) 
Sr.creatinine2(mean) 
e GFR-1 
e GFR-2 
 
58.9 
 
157.9 
23.7 
154.5 
254.8 
6.35 
0.94 
0.88 
0.91 
0.88 
0.73 
0.81 
72.28 
82.33 
7.9 
6.9 
3.3 
27.6 
47 
2.68 
0.18 
0.15 
0.11 
0.15 
0.16 
0.14 
8.12 
13.94 
57.5 
156 
23.6 
90.3 
129 
  0 
0.88 
0.83 
0.86 
0.76 
0.64 
0.70 
76.36 
95.36 
 
9.2 
6.5 
3.1 
13.3 
8.5 
- 
0.15 
0.17 
0.13 
0.15 
0.11 
0.15 
11.5 
13.8 
 
 0.2837 Not significant 
0.0946 Not significant 
0.7914 Not significant 
0.0001 significant 
0.0001 significant 
0.0001 significant 
0.0611 Not significant 
0.1076 Not significant 
0.0544 Not significant 
0.0001  significant 
0.0025   significant 
0.0001significant 
0.1016 Not significant 
0.0008  significant 
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RENAL FUNCTION ANALYSIS 
 
Renal function was analyzed in the two groups. Normal Renal Function 
was observed in 48 patients (96%) in the control group compared to 32 patients 
(61.5%) in the test group. Renal injury was observed in 2 patients (4%) in the 
control group compared to 9 patients (17.3%) in the test group. Renal Failure 
was observed in none of the patients in the control group compared to 11 
patients (21.2%) in the test group. The prevalence of Renal dysfunction was 
more in the study group (38.5%) compared to 4% in controls and the 
difference was statistically significant (p=0.0018). The results are 
summarised in table 6.  
TABLE  6: Renal Function 
 
         Cases Controls     Renal 
Function 
 
No. % No. % 
Normal 32 61.5 48 96 
Renal Injury 9 17.3 2 4 
Renal Failure 11 21.2 - - 
‘p’ 0.0018  significant 
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The relation between age and renal function was analyzed. It was found 
that renal failure was more in patients over 60 years (83.3%) as compared to 
16.1% in the 51-60 years group and 7.7% in the 41-50 years group. 
 
TABLE 7: Age and Renal Function 
 
Renal Function 
Normal Injury Failure 
Age group 
No. % No. % No. % 
Upto 40 years 2 100 - - - - 
41-50      11   84.6      1   7.7      1   7.7 
51-60 19 61.3 7 22.6 5 16.1 
Above 60 years - - 1 16.7 5 83.3 
 
Mean 
S.D. 
 
51.3 
6.8 
 
57.9 
5.3 
 
59.3 
5.9 
‘p’ 0.0005 significant 
 
 
The difference was found to be statistically significant (p=0.0005).  
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TABLE  8: Sex and Renal Function 
 
                                          
                                        Renal Function 
         Normal Injury         Failure 
     
Sex 
 
No. % No %     No % 
 
Males 
(28) 
 
16 
 
57.1 
 
5 
 
17.9 
 
7 
 
25 
 
Females 
(24) 
 
16 
 
66.7 
 
4 
 
16.7 
 
4 
 
16.7 
 
‘p’ 
 
0.6761 Not significant 
 
The difference was not statistically significant (p=0.6761).  
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 TABLE  9: BMI and  Renal Function 
Renal Function 
Normal Injury Failure 
 
BMI 
No. % No. % No. % 
BMI(Total)  
    Underweight(15) 
 
Normal ( 25) 
Overweight ( 12) 
 
10 
16 
6 
 
66.7 
64 
50 
 
3 
3 
3 
 
20 
12 
25 
 
2 
6 
3 
 
13.3 
24 
25 
Mean 
S.D. 
23.5 
2.9 
23.7 
3.9 
24.2 
3.4 
‘p’ 0.7303 Not significant 
BMI(Male)  
    Underweight(9) 
 
Normal ( 12) 
Overweight ( 7) 
 
6 
7 
3 
 
66.7 
58.3 
42.9 
 
2 
1 
2 
 
22.2 
    8.3 
    28.6 
 
1 
4 
2 
 
11.1 
33.3 
28.6 
 Mean 
S.D. 
23.06 
2.65 
23.91 
4.27 
23.9 
2.91 
‘p’ 0.5309 Not Significant 
BMI(Female)  
    Underweight(6) 
 
Normal ( 13) 
Overweight (5) 
 
4 
9 
3 
 
66.7 
69.2 
60 
 
1 
2 
1 
 
16.7 
15.4 
20 
 
1 
2 
1 
 
16.7 
15.4 
20 
Mean 
S.D. 
23.87 
3.2 
23.5 
3.96 
24.59 
4.54 
‘p’ 0.995 Not Significant 
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The relation between duration of disease and renal dysfunction was 
analyzed. It was seen that 10 out of 12 patients (83.3%) with a longer duration 
of disease (>8 years) had renal failure compared to one out of 13 patients (7.7%) 
with duration of disease between 6-8 years. None of the patients with duration 
of disease <6 years had renal failure.  The values are summarized in table 10. 
 
TABLE 10: Duration of Disease and Renal Function 
 
  Renal Function 
Normal Injury Failure 
 
Duration of 
Diseases No. % No. % No. % 
<6 years(27) 
6-8 years(13) 
>8 years(12) 
26 
6 
- 
96.3 
46.2 
- 
1 
6 
2 
3.7 
46.2 
16.7 
- 
1 
10 
- 
7.7 
83.3 
Mean 
S.D. 
4.62 
1.01 
7.33 
1.32 
10.55 
1.51 
‘p’ 0.0001 Significant 
 
 
. The difference was found to be statistically significant (p=0.0001).  
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 Analysis was done in relation to urine PCR and renal dysfunction. It was 
found that abnormal urine PCR was seen in 20 patients at 120 minutes 
compared to none at 0 minutes. Eleven  out of these 20 patients (55%) had 
renal failure and 9 out of 20 patients (45%) had renal injury. The results are 
presented in the following table 11. 
TABLE  11: Urine PCR  and  Renal Function 
 
Renal Function 
Normal Injury Failure 
Urine         PCR 
No. % No % No % 
O min 
Normal(52) 
Abnormal(0) 
 
32 
- 
 
61.5 
- 
  
 9 
- 
   
 
17.3 
- 
 
11 
- 
 
21.2 
- 
‘p’ - 
120 min 
Normal(32) 
Abnormal(20) 
 
32 
- 
 
100 
- 
  
- 
9 
 
 
- 
45 
 
- 
11 
 
- 
55 
‘p’ 0.0001 Significant  
 
. The difference was found to be statistically significant (p=0.0001).  
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 The results of Quantative parameters and Renal Function are 
summarised in the following  table 12.  
  
TABLE  12: Quantitative parameters and  Renal Function 
                   Renal Function 
Normal Injury Failure 
 
      Parameter 
Mean SD Mean SD Mean SD 
        
       ‘p’         
Blood sugar(0 min) 
Blood sugar(120min) 
Sr.creatinine(0min) 
Sr.creatinine(30min) 
Sr.creatinine1(mean) 
Sr.creatinine(60min) 
S.creatinine(120min) 
Sr.creatinine2(mean) 
e GFR-1 
e GFR-2 
 
136.2 
227.5 
0.93 
0.88 
0.91 
0.85 
0.65 
0.75 
73.1 
88.9 
11.0 
31.3 
0.18 
0.15 
0.1 
0.12 
0.1 
0.09 
8.2 
11.2 
173.3 
296.9 
  0.91 
0.84 
0.87 
0.83 
0.76 
0.8 
71.0 
77.6 
 
20.8 
36.4 
0.22 
0.17 
0.17 
0.18 
0.17 
0.16 
7.5 
9.6 
 
192.4 
299.5
0.95 
0.89 
0.94 
1.03 
0.94 
0.98 
70.9 
67.1 
14.2
31.5
0.16
0.14
0.11
0.12
0.12
0.11
8.9 
10.7  
0.0001(S) 
0.0001(S) 
0.8519(NS)
0.802(NS) 
0.3995(NS)
0.0019(S) 
0.0001(S) 
0.0001(S) 
0.4887(NS)
0.0001(S) 
 
 
Fasting serum creatinine levels (0 min), and post load serum creatinine 
levels (30min, 60min and 120min) were analysed in relation to renal function. 
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 The mean serum creatinine-1(0 and 30 min) values were 0.91mg/dl in 
group with Normal Renal Function, 0.87mg/dl in group with Renal Injury, 
0.94mg/dl in group with Renal Failure.  
The mean post protein load serum creatinine-2 values (60 and 120 min) 
were 0.75mg/dl in group with Normal Renal Function , 0.8 mg/dl in group with 
Renal Injury , 0.98mg/dl in group with Renal Failure. 
 Serum creatinine-2 values remained persistently elevated in patients 
with Renal Injury and patients in group with Renal Failure compared to 
patients in group with Normal Renal Function. The relationship was 
statistically significant. (p=0.0001). 
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 DISCUSSION 
Diabetes remains a common menace in the developing population and 
the number has been increasing at an alarming rate in the recent years. The key 
to successful prevention of complications lies in early diagnosis and control. 
The United Kingdom Prospective Diabetes Study, conducted from 1976 to 
1997, showed conclusively that, in people with improved blood glucose control, 
the risk of early kidney disease was reduced by a third.  
Additional studies conducted over the past decades have clearly 
established that any program resulting in sustained lowering of blood glucose 
levels will be beneficial to patients in the early stages of CKD. 
Despite adequate control of diabetes, patients may land up with one or 
more of the macro vascular or micro vascular complications. Diabetic 
nephropathy is a common problem and it remains one of the challenges for us 
to diagnose the presence of renal dysfunction at an early stage. Early diagnosis 
of renal dysfunction in our patients would allow us to protect our patients from 
treatments that may damage further nephrons and tip them into the clinical 
stages of renal failure and to initiate renoprotective management regimens at an 
early stage 
  The early diagnosis is a challenge because the kidney has considerable 
functional reserve so that standard laboratory tests for renal function can only 
detect abnormalities once more than 66% of functioning renal tissue has been 
lost. Precise evaluation of renal function would also allow more effective  
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monitoring of the rate of decline of renal function over time and help determine 
the efficacy of a therapeutic intervention.  
 Many of the results in this study correlated well with literature. There 
was an age related decline in GFR similar to that seen in most studies in the 
past. Around 85% of patients in this study above 60 years had renal failure 
compared to only 13% in age group <60 years. The following graph shows the 
age related decline in GFR as studied in the MDRD study. This was as a result 
of natural history of renal disease as well as increase in conditions like diabetes 
and hypertension. 
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It was found in our study that increase in duration of diabetes was strongly 
related to renal failure. This is well in concurrence with the study done by 
coulhon et al where it was seen that increasing age and duration of diabetes 
were associated with renal failure in Type 2 and Type 1 diabetes. In Type 2 
diabetes duration of diabetes was a more important risk factor than age.  
In the same study, both Type I and Type II diabetic retinopathy and 
proteinuria were strongly associated with renal failure. This was also seen in 
our study where 55% of patients with abnormal urine PCR had renal failure. 
The protein tolerance test is an upcoming investigation and has not been 
extensively evaluated in the past. Very few studies have utilised this test to 
identify patients at risk of renal dysfunction. 
Protein tolerance test was developed way back in 1950 by Horn et al 
where they proved that PTT could identify early onset diabetic nephropathy 
based on the fact that protein loading could exert a stress on both the glomeruli 
and tubules. Subsequently no major study has been done with regard to PTT. In 
this study it was seen that the mean creatinine- 2 values (post protein challenge) 
were more in patients with renal failure compared to those with renal 
dysfunction and normal renal function. The decline in eGFR-2 (post protein 
challenge) was also statistically significant (67 in renal failure versus 88 in 
normal renal function) implying that this could be a useful marker of renal 
reserve. Though there are no major studies for comparison, the results of the 
study were quite significant statistically. This can be done on a larger scale to 
prove the utility of the protein tolerance test.    
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 Protein tolerance test can be very useful to detect incipient renal failure 
in a person with normal GFR and serum creatinine value, thus identifying the 
patients who are most likely to be benefited by an aggressive intervention. This 
is especially important in evaluating high risk persons like diabetics, post-renal 
transplants, and polycystic kidney disease patients. PTT can also be used to 
check the borderline renal donor, and to give accurate prognostication in a 
progressive renal disease. Tubular stress test still requires standardisation and 
further studies to prove its utility. 
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                                                 Summary 
The study “impaired protein tolerance test as a marker of early renal 
dysfunction in type 2 diabetes mellitus” was undertaken to find out the 
usefulness of protein tolerance test in detecting patients with type 2 diabetes 
mellitus who were at risk of developing renal dysfunction. 
The present study was a case control study done at Govt. Rajaji Hospital 
Madurai. After institutional Ethical Committee clearance, 52 patients with type 
2 diabetes mellitus and 50 healthy controls were selected according to the 
inclusion criteria. There were almost equal males and females in the study. A 
baseline fasting and post prandial blood sugar, serum creatine and baseline 
GFR was calculated. This was followed by a protein challenge with 100 grams 
of protein food. Serum creatinine and GFR were measured at 30, 60 and 120 
minutes after protein challenge. Using statistical data, correlation was analyzed 
between pre/post protein challenge serum creatinine in cases and controls in 
relation to GFR and renal function. It was found that patients with renal failure 
had more persistent elevation of serum creatinine and sustained decrease in 
GFR as compared to patients with normal renal function or those with mild 
renal dysfunction. There was also an age related decline in renal function. 
Proteinuria was found to be an independent risk factor for renal failure. 
  It was also found that patients with long duration of diabetes and poor 
glycemic control have more chance of early renal injury and dysfunction than 
those with short duration of diabetes and good glycemic control . 
 49
                                            
 Conclusions 
 
1. Kidney damage starts in Diabetic patients even before microalbuminuria and 
clinical nephropathy starts.  
2. It was found that longer the Duration of diabetes ,more the chance of early 
renal injury and dysfunction. 
3. Renal injury and dysfunction directly correlates with poor metabolic control. 
4. Protein tolerance test can be a very useful test to detect such incipient renal   
failure in patients with normal GFR and normal serum creatinine values. 
 5. Identifying those patients with subnormal renal function may enable us to 
initiate an early aggressive intervention. 
6. This Protein Tolerance Test may be very much useful in high risk patients 
like Diabetics,Hypertensive patients. 
7. Patients with diseases like solitary kidney, polycystic kidney disease, post 
renal transplants can also be subjected to this test to identify incipient renal 
failure. 
8. Protein Tolerance Test can also be used to check the borderline renal donor 
in order to give accurate prognostication in a progressive renal disease. 
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                                             PROFORMA 
 
Name:                                  Age:                     Sex: 
 
Occupation:                         Address: 
 
Height:                                 ID: 
Weight: 
BMI: 
 
Duration of Diabetes:           yrs 
Hypertension:               yes / no  
Renal Disease:              yes /no 
Diabetic Nephropathy: yes / no 
 
Diet History: 
Personal History: 
Family History: 
 
General examination: 
Pulse:             Blood pressure:                 Temp:                  RR: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
 
Investigations: 
Blood TC:                DC:                              HB:                ESR: 
Blood Urea:               Urine Alb:          Sugar:              Dep:    
 
Blood Sugar:        0 hour:                            2hour: 
 
Serum Creatinine: 0 min:              30min:            mean1:          e GFR1: 
                            60min              120min:          mean2:          e GFR2: 
Urine PCR:          0min:                                    120min: 
 
Renal Function Result: 
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S.NO ID Age sex weight height BMI BS-0hr BS-2hr Duration sc-0 sc30 sc1mean e GFR1 sc60 sc120 sc2mean e GFR2 PCR(0) PCR(120) Renal Function GROUP
1 T36 52 M 76 165 Overweight 216 324 7 1.2 1.1 1.15 80.77 1.1 1.1 1.1 84.12 N A I II
2 T52 45 M 70 160 Overweight 146 224 5 1.2 1 1.1 89.62 1 0.8 0.9 102.62 N N N I
3 T3 60 M 68 156 Overweight 196 344 9 1.1 1 1.05 71.95 1.1 1.1 1.1 68.42 N A F III
4 T7 37 M 66 154 Overweight 132 248 3 1.2 1.1 1.15 82.1 1 0.8 0.9 104.9 N N N I
5 T5 46 M 68 158 Overweight 128 246 4 1.1 1.1 1.1 80.4 1 0.8 0.9 98.64 N N N I
6 T10 55 M 74 160 Overweight 164 302 5 1.2 1 1.1 79.11 1 0.9 0.95 91.95 N A I II
7 T20 57 M 69 159 Overweight 208 278 11 1.1 1 1.05 75.55 1.2 1.1 1.15 69.16 N A F III
8 T22 50 M 53 154 Normal 134 240 6 0.8 1 0.9 73.61 1 0.6 0.8 82.81 N N N I
9 T23 57 M 61 164 Normal 186 272 10 1.1 1 1.05 66.97 1.2 1 1.1 63.68 N A F III
10 T24 51 M 62 165 Normal 128 240 5 1.1 0.9 1 76.64 1 0.6 0.8 95.8 N N N I
11 T25 65 M 60 162 Normal 174 298 12 1 0.8 0.9 69.44 1 1 1 62.5 N A F III
12 T26 58 M 61 164 Normal 136 202 6 1.2 0.8 1 69.47 0.8 0.8 0.8 86.84 N N N I
13 T27 54 M 56 158 Normal 128 198 5 1.1 1 0.9 74.32 0.8 0.6 0.7 95.55 N N N I
14 T28 58 M 58 160 Normal 168 302 8 0.8 0.9 0.85 77.71 0.8 0.8 0.8 82.56 N A I II
15 T17 55 M 61 162 Normal 194 320 10 1 1 1 70.01 1.1 1 1.05 68.58 N A F III
16 T32 43 M 63 160 Normal 130 210 5 0.8 1.2 1 84.8 1 0.6 0.8 106.09 N N N I
17 T19 56 M 62 158 Normal 132 244 5 1 1 1 72.33 0.8 0.9 0.85 85.09 N N N I
18 T21 55 M 48 146 Normal 138 216 4 0.8 1 0.9 62.96 1 0.5 0.75 75.55 N N N I
19 T11 45 M 65 165 Normal 178 320 9 0.8 1 0.9 95.29 1 0.8 0.9 95.29 N A F III
20 T18 62 M 51 167 Underweight 180 316 8 0.6 1 O.8 69.06 0.9 0.8 0.85 65 N A F III
21 T35 60 M 50 165 Underweight 152 240 6 O.8 0.8 0.8 69.44 0.7 0.8 0.75 74.07 N A I II
22 T20 42 M 54 170 Underweight 136 280 3 1 0.6 0.8 91.88 0.8 0.6 0.7 105 N N N I
23 T15 46 M 48 163 Underweight 131 215 4 0.9 0.7 0.8 78.33 0.6 0.6 0.6 104.44 N N N I
24 T29 56 M 57 176 Underweight 126 184 5 1.2 0,8 1 66.5 0.8 0.8 0.8 83.12 N N N I
25 T30 57 M 55 173 Underweight 122 168 2 1 0.6 0.8 79.45 0.6 0.6 0.6 105.67 N N N I
26 T48 57 M 48 163 Underweight 145 214 5 0.6 1 0.8 69.16 0.7 0.5 0.6 92.22 N N N I
27 T33 60 M 45 162 Underweight 166 348 9 0.6 1 0.8 62.5 0.8 0.7 0.75 66.66 N A I II
28 T39 53 M 52 168 Underweight 130 242 4 1.1 0.8 0.95 66.14 0..9 0.7 0.8 78.54 N N N I
29 T31 60 F 68 155 Overweight 178 298 7 1 0.8 0.9 71.35 1 0.6 0.8 80.28 N A I II
30 T1 55 F 75 157 Overweight 137 206 4 0.9 0.9 0.9 83.62 1 0.6 0.8 94.07 N N N I
31 T2 65 F 68 148 Overweight 212 234 13 1 0.9 0.95 63.37 1 1 1 60.2 N A F III
32 T4 56 F 65 160 Overweight 138 202 6 1 0.8 0.9 71.62 0.8 0.6 0.75 85.94 N N N I
33 T34 50 F 67 145 Overweight 135 268 4 1 0.8 0.9 79.09 0.8 0.6 0.7 101.69 N N N I
34 T3 59 F 62 166 Normal 198 302 12 1 0.8 0.9 65.87 1 0.9 0.95 62.4 N A F III
35 T6 55 F 44 143 Normal 122 196 4 0.8 0.8 0.8 63.63 0.8 0.6 0.7 72.72 N N N I
36 T8 49 F 49 142 Normal 152 243 8 0.8 0.6 0.7 73.54 0.6 0.6 0.6 85.8 N A I II
37 T9 45 F 55 151 Normal 147 220 5 0.6 1 0.8 77.1 0.8 0.6 0.7 88.06 N N N I
38 T12 65 F 53 148 Normal 178 280 11 0.8 0.7 0.75 62.57 1 0.8 0.9 52.14 N A F III
39 T13 48 F 55 150 Normal 138 238 3 1 0.8 0.9 68.53 0.8 0.6 0.7 85.33 N N N I
40 T38 56 F 57 153 Normal 126 240 6 0.9 0.7 0.8 70.65 0.8 0.6 0.7 80.75 N N N I
41 T40 32 F 52 153 Normal 138 256 4 0.8 1 0.9 73.66 0.8 0.6 0.7 94.69 N N N I
42 T41 55 F 61 164 Normal 146 248 5 1 1 1 61.21 1 0.8 0.9 68.01 N N N I
                                                                                                                                            MASTER     CHART
43 T43 60 F 58 160 Normal 196 328 9 1 0.8 0.9 60.86 0.9 0.7 0.85 63.82 N A I II
44 T44 60 F 51 152 Normal 170 268 6 0.6 1 0.8 60.18 0.8 0.6 0.7 68.81 N N N I
45 T45 55 F 60 164 Normal 146 278 4 0.8 0.9 0.85 70.83 0.8 0.7 0.75 80.27 N N N I
46 T46 60 F 62 162 Normal 138 226 5 1 0.8 0.9 65.06 1 0.6 0.8 86.11 N N N I
47 T47 50 F 47 160 Underweight 112 138 5 0.6 0.8 0.7 71.33 0.7 0.6 0.65 76.83 N N N I
48 T49 62 F 45 158 Underweight 212 330 11 0.7 0.6 0.65 63.75 0.7 0.6 0.65 63.75 N A F III
49 T50 60 F 43 154 Underweight 158 246 6 0.7 0.6 0.65 62.47 0.6 0.6 0.6 67.68 N N N I
50 T51 44 F 50 165 Underweight 144 232 5 0.9 0.8 0.85 66.66 0.8 0.6 0.7 80.95 N N N I
51 T14 67 F 48 162 Underweight 168 287 7 0.7 0.6 0.65 63.64 0.6 0.6 0.6 68.94 N A I II
52 T16 54 F 49 163 Underweight 142 248 5 0.6 0.7 0.75 66.33 0.7 0.6 0.65 76.54 N N N I
53 C1 60 M 68 164 Overweight 90 134 0 1.1 0.9 1 75.55 0.8 0.6 0.7 107.93 N N N C
54 C2 47 M 74 162 Overweight 98 136 0 0.8 1 0.9 106.2 0.9 0.8 0.85 114.86 N N N C
55 C3 60 M 78 164 Overweight 102 140 0 1.2 0.8 1 86.66 1 0.7 0.85 104.5 N N N C
56 C4 56 M 72 164 Overweight 98 138 0 1 1 1 94 1 0.7 0.85 101.17 N N N C
57 C5 50 M 70 168 Overweight 108 132 0 1.2 1.2 1.2 72.91 1.2 0.7 0.95 92.1 N N N C
58 C6 39 M 62 159 Normal 106 128 0 1.2 0.8 1 86.97 1 0.6 0.8 108.71 N N N C
59 C7 36 M 70 168 Normal 86 126 0 0.9 1.2 1.05 96.29 0.9 0.8 0.85 118.95 N N N C
60 C8 55 M 60 158 Normal 94 132 0 0.8 1.2 1 70.83 0.7 0.8 0.75 98.88 N N N C
61 C9 35 M 45 144 Normal 82 120 0 0.8 0.6 0.7 93.75 0.6 0.6 0.6 111.45 N N N C
62 C10 59 M 60 158 Normal 94 138 0 1 1 1 67.5 0.7 0.8 0.75 92.22 N N N C
63 C11 58 M 54 152 Normal 68 116 0 0.8 0.7 0.75 82 0.6 0.6 0.6 105 N N N C
64 C12 57 M 56 158 Normal 96 136 0 0.7 0.9 0.8 80.6 0.7 0.7 0.7 94.44 N N N C
65 C13 40 M 64 162 Normal 84 128 0 1 0.9 0.95 93.56 0.8 0.8 0.8 111.11 N N N C
66 C14 59 M 58 155 Normal 64 116 0 0.8 0.9 0.85 76.76 0.9 0.6 0.75 89.14 N N N C
67 C15 60 M 60 158 Normal 104 140 0 1.1 0.9 1 66.66 0.9 0.9 0.9 70.17 N A I C
68 C16 49 M 54 153 Normal 74 128 0 0.9 0.7 0.8 85.31 0.7 0.6 0.65 109.61 N N N C
69 C17 45 M 62 158 Normal 96 124 0 1.1 1.1 1.1 74.36 0.9 0.8 0.85 98.26 N N N C
70 C18 56 M 58 156 Normal 98 126 0 1 1 1 67.66 0.6 0.8 0.7 101.26 N N N C
71 C19 66 M 60 158 Normal 85 124 0 0.8 1 0.9 68.51 0.7 0.6 0.65 108.33 N N N C
72 C20 36 M 48 164 Underweight 102 136 0 0.8 0.6 0.7 99.04 0.7 0.5 0.6 117.77 N N N C
73 C21 36 M 56 174 Underweight 76 140 0 1 0.8 0.9 89.87 0.8 0.8 0.8 105 N N N C
74 C22 37 M 52 170 Underweight 110 137 0 0.9 0.8 0.85 87.51 0.6 0.8 0.7 108.33 N N N C
75 C23 38 M 45 156 Underweight 69 118 0 0.7 0.8 0.75 85 0.7 0.6 0.65 100 N N N C
76 C24 50 M 46 158 Underweight 98 125 0 0.8 0.8 0.8 71.87 0.8 0.6 0.7 82.14 N N N C
77 C25 60 M 54 172 Underweight 90 134 0 0.8 1 0.9 66.66 0.9 0.6 0.75 82 N N N C
78 C26 47 M 53 170 Underweight 92 136 0 0.9 0.6 0.75 91.27 0.6 0.7 0.65 107.58 N N N C
79 C27 56 F 70 147 Overweight 86 132 0 1 1 1 69.41 0.8 0.7 0.75 96.96 N N N C
80 C28 69 F 67 154 Overweight 104 136 0 0.8 1 0.9 62.39 1 0.6 0.8 72.17 N N N C
81 C29 60 F 60 152 Overweight 98 108 0 1 0.8 0.9 62.96 0.8 0.7 0.75 75.55 N N N C
82 C30 48 F 74 165 Overweight 104 138 0 1 1 1 80.37 1 0.6 0.8 102.64 N N N C
83 C31 50 F 53 145 Overweight 106 126 0 0.8 0.6 0.7 80.44 0.6 0.5 0.55 104.66 N N N C
84 C32 49 F 50 142 Overweight 94 132 0 0.9 0.6 0.75 71.62 0.6 0.5 0.55 101.95 N N N C
85 C33 56 F 78 164 Overweight 64 110 0 1 0.9 0.95 81.42 0.9 0.8 0.8 101.29 N N N C
86 C34 60 F 56 165 Normal 94 132 0 0.8 0.8 0.8 66.04 0.7 0.5 0.6 88.14 N N N C
87 C35 43 F 66 164 Normal 96 126 0 0.9 0.8 0.85 88.91 0.8 0.6 0.7 110.19 N N N C
88 C36 59 F 62 160 Normal 72 132 0 1 0.9 0.95 62.4 0.8 0.7 0.75 81 N N N C
89 C37 50 F 50 148 Normal 82 116 0 0.8 0.7 0.75 70.83 0.6 0.5 0.55 96.59 N N N C
90 C38 50 F 50 150 Normal 98 138 0 0.9 0.7 0.8 66.4 0.8 0.6 0.7 75.89 N N N C
91 C39 67 F 51 148 Normal 76 124 0 0.8 0.6 0.7 62.78 0.6 0.5 0.55 82.1 N N N C
92 C40 48 F 55 154 Normal 82 130 0 0.8 0.8 0.9 66.37 0.8 0.5 0.65 95.89 N N N C
93 C41 40 F 54 152 Normal 66 108 0 0.9 0.8 0.85 74.99 0.7 0.6 0.65 98.07 N N N C
94 C42 57 F 50 150 Normal 88 126 0 0.6 0.8 0.7 69.99 0.6 0.6 0.6 85.51 N N N C
95 C43 64 F 56 158 Normal 102 128 0 0.8 0.6 0.7 73.67 0.8 0.5 0.65 79.33 N N N C
96 C44 60 F 50 152 Normal 92 136 0 0.7 0.8 0.75 62.96 0.7 0.5 0.6 78.7 N N N C
97 C45 58 F 52 168 Underweight 98 126 0 0.8 0.8 0.8 62.92 0.8 0.5 0.65 77.44 N N N C
98 C46 60 F 43 154 Underweight 108 136 0 0.7 0.6 0.65 62.48 0.6 0.6 0.6 67.68 N A I C
99 C47 59 F 44 158 Underweight 76 134 0 0.6 0.8 0.7 60.1 0.6 0.6 0.6 90.31 N N N C
100 C48 47 F 48 161 Underweight 62 118 0 0.8 0.6 0.7 75.28 0.6 0.6 0.6 91.61 N N N C
101 C49 54 F 46 162 Underweight 98 132 0 0.6 0.8 0.7 66.71 0.6 0.6 0.6 79.65 N N N C
102 C50 50 F 47 160 Underweight 106 138 0 0.8 0.6 0.7 74.5 0.6 0.6 0.6 86 N N N C
N Normal
A Abnormal
I Injury
F Failure
